SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about updates

04 Oct 2025 Evaluate
With reference to intimation dated July 17, 2025 and with respect to the inspection undertaken by US FDA at Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025, wherein the inspection was closed with the issuance of a Form-483 with four observations, Lupin has informed that US FDA has determined the inspection classification of this facility as ‘Official Action Indicated (OAI)’. The Company is working with the US FDA to satisfactorily resolve the compliance issues and is committed to be compliant with CGMP standards at all its manufacturing facilities. 

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×